Estimating Rebates and Other Discounts Received by Medicare Part D
- 4 June 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Health Forum
- Vol. 2 (6) , e210626
Abstract
Medicare Part D spending represents nearly one-third of retail prescription drug spending in the US.1 Researchers have examined a variety of strategies to limit spending, including international reference pricing,2 direct price negotiation,3-5 and substitution of less expensive but therapeutically equivalent products.6-10 Studies modeling the effects of such policy changes on Medicare Part D spending have a common limitation: none can fully account for confidential rebates or other discounts that drug manufacturers and pharmacies provide to Medicare Part D plans.Keywords
This publication has 18 references indexed in Scilit:
- Potential Medicare Savings From Generic Substitution and Therapeutic Interchange of ACE Inhibitors and Angiotensin-II-Receptor BlockersJAMA Internal Medicine, 2019
- Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic PrecursorsAnnals of Internal Medicine, 2019
- Analysis of State-Level Drug Pricing Transparency Laws in the United StatesJAMA Network Open, 2019
- Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other CountriesHealth Affairs, 2019
- Assessment of Spending in Medicare Part D If Medication Prices From the Department of Veterans Affairs Were UsedJAMA Internal Medicine, 2019
- Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription DrugsJAMA Internal Medicine, 2019
- Medicare Spending on Brand-name Combination Medications vs Their Generic ConstituentsJAMA, 2018
- Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015JAMA Internal Medicine, 2018
- Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal SpendingJAMA Internal Medicine, 2017
- Medicare Part D Payments for Topical SteroidsJAMA Dermatology, 2017